(Recasts; adds details)
Oct 27 Barr Pharmaceuticals Inc BRL.N said
the U.S. regulators approved an oral contraceptive made by its
unit Duramed Pharmaceuticals Inc.
Barr, which agreed to be bought by Israel-based Teva
Pharmaceutical Industries Ltd TEVA.O for $7.46 billion in
July, said the drug, LoSeasonique, would be available by
prescription to women in the first quarter of 2009. The drug's
extended-cycle regimen, indicated for prevention of pregnancy,
is designed to reduce the number of withdrawal bleeding periods
from 13 to four per year, the company said in a statement.
Withdrawal bleeding is experienced each month when a woman
uses a hormonal birth control method.
Shares of Barr were down 56 cents at $58.58 in early
morning trade on the New York Stock Exchange.
(Reporting by Esha Dey in Bangalore; Editing by Anil